BDC-1001 is a novel HER2-targeting TLR7/8 ISAC that is currently under investigation in the setting of early phase clinical trials (NCT04278144)33, both as monotherapy and in combination with immune checkpoint inhibitors in patients with advanced HER2-driven cancers. Here, ERBB2 is linked to cancer.